Articles

Enrollment in clinical trials is vital for the advancement of knowledge and improvement of patient outcomes, but few adults participate in cancer clinical trials. Read More ›

Pevonedistat plus Azacitidine Combination Shows Encouraging Activity in Higher-Risk MDS

By William King

Hematologic Malignancies

TON - April 2021 Vol 14, No 2

The combination of the investigational drug pevonedistat in combination with azacitidine injection (Vidaza) leads to longer event-free survival (EFS) and a higher complete response rate than azacitidine alone in patients with high-risk myelodysplastic syndromes (MDS), according to results from a phase 2, open-label, international clinical trial. Read More ›

Promising Results Seen with Ruxolitinib as Second-Line Treatment for Chronic GVHD

By Patricia Stewart

Hematologic Malignancies

TON - April 2021 Vol 14, No 2

In a phase 3 clinical trial, ruxolitinib (Jakafi) led to superior overall response rates and durable responses compared with best available therapy (ie, control group) in patients with steroid-dependent or steroid-refractory chronic graft-versus-host disease (GVHD), with acceptable safety, according to results presented at ASH 2020. Read More ›

Fixed-Duration Ibrutinib plus Venetoclax Regimen Promising as First-Line Treatment in CLL

By Patricia Stewart

Hematologic Malignancies

TON - April 2021 Vol 14, No 2

The randomized phase 2 CAPTIVATE clinical trial showed that first-line therapy with ibrutinib (Imbruvica) and venetoclax (Venclexta) for a fixed duration (ie, 12 cycles) led to a 30-month progression-free survival (PFS) in more than 95% of patients with chronic lymphocytic leukemia (CLL) and undetectable minimal residual disease (MRD). Read More ›

Assessing Patient and Clinicians’ Attitudes about the Usability of Telehealth During the COVID-19 Pandemic

Breast Cancer

Web Exclusives

In the cancer care setting, telehealth was perceived favorably by patients and providers, providing a new pathway for accessing treatment in the future. Read More ›

Understanding Patient Perceptions of De-Escalating Chemotherapy During the COVID-19 Pandemic

Breast Cancer

Web Exclusives

The pandemic shifted patients’ fears, highlighting the critical importance of physician trust and language used in recruitment. Read More ›

Oncology Nurses Who Adopted “Care and Coping” Principles Served as the Hub of Services within the Inpatient and Ambulatory Care Setting

Breast Cancer

Web Exclusives

The delivery of care transformed rapidly as healthcare systems innovated to handle the COVID-19 pandemic. The overarching goals and principles of cancer care did not change, but there was a heightened recognition of the challenges faced by cancer patients. Read More ›

The Combination of Ribociclib plus Endocrine Therapy Improves Health-Related Quality of Life in Premenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Breast Cancer

Web Exclusives

The latest quality-of-life research from the MONALEESA-7 trial supports a strong clinical benefit-to-risk ratio with ribociclib-based treatment in pre- and perimenopausal patients. Read More ›

Role of Telehealth During the COVID-19 Pandemic Across the Interdisciplinary Cancer Care Team

Breast Cancer

Web Exclusives

In the future, telehealth may help overcome obstacles to healthcare access for underserved populations. Read More ›

Emerging Combination Therapies in Renal-Cell Carcinoma: Applying the Lessons from Clinical Trials to Clinical Practice

Clinical Trials

March 2021 Clinical Trials to Clinical Practice